The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview

Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortality rates among all cancer types. Its delayed diagnosis precludes curative resection, thus most of the current therapies against PDAC are based on chemo- and radiotherapy. Unfortunately, these strategies are insufficient to improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Quiñonero, Francisco, Mesas, Cristina, Doello, Kevin, Cabeza, Laura, Perazzoli, Gloria, Jimenez-Luna, Cristina, Rama, Ana Rosa, Melguizo, Consolación, Prados, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936232/
https://www.ncbi.nlm.nih.gov/pubmed/31908888
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936232/
https://www.ncbi.nlm.nih.gov/pubmed/31908888
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0252

Ejemplares similares